nach oben

Erschienen in:

01.09.2014 | Original Article

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions

verfasst von: J. J. Koldenhof, P. O. Witteveen, R. de Vos, M. Walraven, C. N. Tillier, H. M. W. Verheul, S. C. C. M. Teunissen

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Optimal long-lasting treatment with sunitinib and sorafenib is limited by dose modifications (DMs) due to adverse events (AEs). These AEs may be underrecognized and their influence on health-related quality of life (HRQL) underestimated. Improved insight into the relationship between AEs and therapy decisions is needed. To improve decision making around managing symptoms and reduce DMs, this study was set up to explore the influence of patient-reported symptoms on therapy decisions.

Methods

In this multicenter cohort study, patient characteristics, reasons for and different forms of used dose modifications, and AEs were prospectively obtained from cancer patients on sunitinib/sorafenib treatment. Used instruments to get insight into AEs were the patient-scored Utrecht Symptom Diary (USD) and the professional-scored Common Terminology Criteria for AEs version 3.0.

Results

Median total treatment duration in 42 patients was 16 weeks. Median time till dose modification was 10 weeks. DMs occurred mostly due to multiple mild AEs. By using the USD, a higher prevalence of most AEs was found compared to the literature. Sixty percent of the patients experienced a decreased HRQL due to multiple AEs.

Conclusions

Because severe AEs due to sunitinib/sorafenib treatment seldom occur, it is more important to focus on treating and preventing multiple mild AEs with higher impact on HRQL, when trying to avoid dose modifications. Using patient self-reported measurement methods helps to early recognize symptoms and to differentiate among symptom intensities. This systematic approach might help to achieve the optimal dosing, which might improve PFS and OS.

Porta C, Szczylik C (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 35:297–307PubMedCrossRef

Hutson TE (2007) Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Rev Anticancer Ther 7:1193–1202PubMedCrossRef

van der Veldt AA, Boven E, Helgason HH et al (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259–265PubMedCentralPubMedCrossRef

Houk BE, Bello CL, Poland B et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357–371PubMedCrossRef

Maluf FC, Fernandes GS, Kann AG et al (2008) Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treat Rev 34:750–760PubMedCrossRef

Wolter P, Schoffski P (2010) Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol 49:13–23PubMedCrossRef

Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300PubMedCrossRef

Gupta K, Miller JD, Li JZ et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34:193–205PubMedCrossRef

Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12:1404–1415PubMedCrossRef

10.

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef

11.

La Vine DB, Coleman TA, Davis CH et al (2010) Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 33:217–220PubMed

12.

Herrmann E, Bierer S, Gerss J et al (2008) Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology 74:216–222PubMedCrossRef

13.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

14.

CTCAEversion3.0; http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. 2011. 15-2-2011. Ref Type: Online Source

15.

McCaffery M, Ferrell BR (1997) Nurses’ knowledge of pain assessment and management: how much progress have we made? J Pain Symptom Manag 14:175–188CrossRef

16.

Gill A, Daines P, Selby D (2010) What do symptom scores mean: observations on discrepancies when defining symptoms using words and numbers. Eur J Oncol Nurs 14:435–438PubMedCrossRef

17.

Selby D, Cascella A, Gardiner K et al (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manag 39:241–249CrossRef

18.

Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed

19.

Richardson LA, Jones GW (2009) A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 16:55PubMedCentralPubMed

20.

Philip J, Smith WB, Craft P et al (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6:539–541PubMedCrossRef

21.

Teunissen SC, de Graeff A, de Haes HC et al (2006) Prognostic significance of symptoms of hospitalised advanced cancer patients. Eur J Cancer 42:2510–2516PubMedCrossRef

22.

Teunissen SC, Wesker W, Kruitwagen C et al (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag 34:94–104CrossRef

23.

Investigator’s brochure BAY43--9006. 1-4-2007

24.

Investigator’s brochure sunitinib malate. 1-4-2007

25.

de Boer AG, van Lanschot JJ, Stalmeier PF et al (2004) Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 13:311–320PubMedCrossRef

26.

Bonett DG, Price RM (2002) Statistical inference for a linear function of medians: confidence intervals, hypothesis testing, and sample size requirements. Psychol Methods 7:370–383PubMedCrossRef

27.

Agresti A, Coull BA (1998) Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat Assoc 52:119–126

28.

Cella D (2009) Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 35:733–737PubMedCrossRef

29.

Wagner LI, Wenzel L, Shaw E et al (2007) Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol 25:5058–5062PubMedCrossRef

30.

Wood LS (2009) Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs 13(Suppl):13–18PubMedCrossRef

31.

Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930PubMedCrossRef

32.

McKeage K, Wagstaff AJ (2007) Sorafenib: in advanced renal cancer. Drugs 67:475–483PubMedCrossRef

33.

Mokkink LB, Terwee CB, Patrick DL et al (2010) The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 19:539–549PubMedCentralPubMedCrossRef

34.

Blay JY (2010) Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 21:208–215PubMedCrossRef

35.

Charles C, Gafni A, Whelan T (1999) Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 49:651–661PubMedCrossRef

36.

Stacey D, Samant R, Bennett C (2008) Decision making in oncology: a review of patient decision aids to support patient participation. CA Cancer J Clin 58:293–304PubMedCrossRef

37.

Rini BI (2007) Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13:1098–1106PubMedCrossRef

Titel: Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions
verfasst von: J. J. Koldenhof
P. O. Witteveen
R. de Vos
M. Walraven
C. N. Tillier
H. M. W. Verheul
S. C. C. M. Teunissen
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 9/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2223-2

Springer Medizin

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions